Podocyte injury is the inciting event in primary glomerulopathies, such as minimal change
disease and primary FSGS, and glucocorticoids remain the initial and often, the primary
treatment of choice for these glomerulopathies. Because inflammation is not readily
apparent in these diseases, understanding the direct effects of glucocorticoids on the
podocyte, independent of the immunomodulatory effects, may lead to the identification of
targets downstream of glucocorticoids that minimize toxicity without compromising efficacy …